Huge Japanese Deal Could Boost the Shares of this Mighty Medical Mammoth

Published 41 days ago

Hello, Share Picklers. It’s obvious that medical companies are risky. But the smaller outfits provide more perilous opportunities. The giants seem big enough to absorb the failures and obstacles to obtaining the necessary licences. AstraZeneca (AZN), like GlaxoSmithKline (GSK), is a jumbo pharmaceutical company and is worth a look...

Welcome to your FTSE 100 broker Christmas lunch

Published 152 days ago

Back in the day, I used to be an institutional fund manager and did go on a number of brokerage lunches at around this time of year. The essential underlying aim of these lunches did not change for years: a thank you for business given during the year...and a pitch or ten about stocks that could be bought (or sold) early the next year in order to keep that commission flow going (and from the broker's perspective hopefully building). It seemed to me that the ideas took a very simple form: buy the underperformers and sell the outperformers. Well who does not like a bargain or - indeed - to take profits? So from an akin premise - but with an added slice of cynicism (and no need to elicit your brokerage commission flows!) - what does a 'brokerage lunch list' throw up as interesting in December 2018 looking ahead into 2019?...

Arix Bioscience: Will the Chinese save Woodford’s bacon?

Published 446 days ago

In my conclusion to The Big Short series on Woodford Patient Capital Trust (WPCT), I wondered where new pools of capital could come from to keep these biotech valuations afloat now that Woodford has run out of money and I considered capital from China as a potential life-saver. Two pieces of news this week make me consider this further, one in relation to another long-term short pick of mine in the biotech fund space, namely Arix Bioscience (ARIX).

The Nomates Neil Woodford 2001 excuse/defence - it's just a Maginot line

Published 634 days ago

It is quite amazing to see just how few friends fund manager Neil Woodford has in the City these days. It is almost as if I am starting to feel that he is a kindred spirit. Neil, how about we have a joint Square Mile Christmas party for all of our friends in a telephone kiosk somewhere? The vast fees Nomates has charged for delivering three years of dismal underperformance do not play well but it is the arrogant insistence that Mr Market is always wrong because Nomates knows better that has unleashed such waves of schadenfreude after his latest disasters. But he still has one or two defenders who say "aha remember 2001" - but this Maginot defence does not wash.

It Should Pay to Stick With AstraZeneca, but Patience Is Needed

Published 659 days ago

Hello, Share Spooners. Given the ageing and less healthy world population, I have often said that the big pharmaceuticals offer a buying opportunity. But as usual with medical advances, progress has been slow. I hold shares in GlaxoSmithKline (GSK). But although I’ve often been tempted to dive into its big rival AstraZeneca (AZN), I have resisted the urge. Now I’m rather glad I did.

AstraZeneca May Rise If New Drug Launches Come off

Published 791 days ago

One of the big pharmaceuticals which I think will prosper on the misfortunes of millions of people is AstraZeneca (AZN). This is not to say that the company is exploitative. Quite the opposite - its scientists are only trying to help.

AstraZeneca Escaped Take-Over by Americans, but Still Does a Germ-Zapping Deal with Uncle Sam

Published 994 days ago

Hello Share Smackers. If there is one sector which can be truly called defensive, it is the giant pharma world. Big drugs companies supply something that no-one in his or her right mind would give up - release from pain and suffering. So even when times are hard, medical giants will continue to make money.

A Safer Punt for Lovers of Pharma Shares.

Published 1067 days ago

Hello Share Mongers. The case for investing in large pharma companies remains strong in my book. Maybe it's because I'm getting old, but I see that health is the biggest concern we ought to have. What is money, if we're feeling lousy? Pretty worthless. But there is always a possible danger in investing in companies which produce treatments and drugs. I am heavily into quite a few medical pioneers and I sometimes worry that I should not be sleeping at nights.

As Cancer Treatments Advance it Could Be Time to Look Into AstraZeneca and GlaxoSmithKline

Published 1078 days ago

Hello Share Pitchers. My parents were so frightened of cancer that they refused to utter the word. As a result I had never even heard of the affliction until I was an advanced teenager. These days we all still fear the condition, but we perhaps should not do so as much as we used to. This is because treatments are becoming more effective year on year. It is still an appalling killer, though.

Try a Fiesty Firm Which Helps the Polluted World to Breathe: Vectura.

Published 1130 days ago

Hello Share Munchers. Time to re-visit another bio techie, I think. This weekend, I give you Vectura (VEC). My thinking as usual is that we have a world population that gets sicker by the minute. It’s also getting older which means the raft of complaints us oldies have to suffer is getting vaster, too.

Vectura Could be a Breath of Fresh Air in your Biotech Portfolio.

Published 1204 days ago

Hello Share  Shiners.  All right, this is another article on a promising bio science outfit. Yes, my support for companies which push through the frontiers of medicine is undiminished in 2016.

I Spy With My Little ICI - a Giant Medical Pioneer Probably with a Healthy Future.

Published 1214 days ago

Hello Share Shufflers.  Let’s have a butcher’s at AstraZeneca (AZN). I’ve been blowing the trumpet of quite a few medical punts in the last month or so. And, with a market cap of £54 billion, they don’t get much bigger than this one.

Feel-Good Medical Shares Could Hit Higher Temperatures.

Published 1723 days ago

Hello Share Collectors: There is a growing case for investing in companies, which sell or look for medical cures. I think the big British pharma companies are undervalued and worth a punt.


About ShareProphetsTerms of ServiceForgot My Password
Contact UsPrivacy PolicyForgot My Username
Advertise With UsCookie PolicyResend Account Validation Token
Send Us A Tip

Data by ADVFN / Site by Everywhen /